You are here: Industry Insights > Alexion

News List

AstraZeneca’s Alexion and Neurimmune sign antibody development deal Pharmaceutical-Technology
January 11, 2022
AstraZeneca’s Rare Disease group Alexion and Neurimmune have signed an exclusive worldwide partnership and licence agreement to develop NI006, a human monoclonal antibody.
CHMP recommends expanded use for Alexion’s PNH therapy Ultomiris pharmatimes
July 27, 2021
AstraZeneca’s (AZ) Ultomiris has received a positive recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) to expand its use to include children and adults with ...
AstraZeneca concludes Alexion acquisition for $39bn pharmaceutical-technology
July 23, 2021
AstraZeneca has concluded the acquisition of US-based biopharmaceutical company Alexion Pharmaceuticals for a total consideration of $39bn or $175 per share.
AstraZeneca Completes Acquisition of Alexion americanpharmaceuticalreview
July 22, 2021
AstraZeneca completed the acquisition of Alexion Pharmaceuticals, Inc. (Alexion). The closing of the acquisition marks the Company’s entry into medicines for rare diseases and the beginning of a new chapter for AstraZeneca.
AZ scores final clearance for Alexion acquisition in the UK pharmatimes
July 15, 2021
AstraZeneca (AZ) is expecting its acquisition of Alexion Pharmaceuticals to close on 21 July after receiving final clearance from the UK Competition and Markets Authority (CMA).
AstraZeneca receives EC approval for $39bn Alexion acquisition pharmaceutical-technology
July 07, 2021
The European Commission has cleared the proposed acquisition by AstraZeneca of US-based biopharmaceutical company Alexion Pharmaceuticals for approximately $39bn or $175 a share.
Competition and Markets Authority investigating AstraZeneca’s Alexion acquisition europeanpharmaceuticalreview
May 31, 2021
The UK’s competition authority will assess whether AstraZeneca’s acquisition of Alexion will result in a “substantial lessening of competition”.
NHS patients with rare blood disorders gain access to Ultomiris pharmatimes
May 21, 2021
NHS patients with paroxysmal nocturnal haemoglobinuria (PNH) or atypical haemolytic uraemic syndrome (aHUS) are to get access to treatment with Alexion's Ultomiris (ravulizumab) following a green light from cost regulators.
SMC endorses Alexion’s Ultomiris pharmatimes
May 12, 2021
The Scottish Medicines Consortium (SMC) has accepted a treatment for an ultra-rare disease that can cause progressive injury to vital organs via damage to the walls of blood vessels and blood clots in its May decisions.
AstraZeneca Shareholders Approve Proposed Acquisition of Alexion americanpharmaceuticalreview
May 12, 2021
A requisite majority of AstraZeneca shareholders has approved the proposal to acquire the entire common stock of Alexion Pharmaceuticals, Inc. (Alexion) at a general meeting.

Previous page 1 2 3 4 5 Next page